Heading to AMP in Seattle, November 12–14? Visit GTC at booth 1812 and catch Dr. Ahmad Charifa’s talk on November 12 at 12:40 p.m., exploring RNA expression profiling and AI as an alternative to traditional IHC.
Meet our team and discover the power of DNA + RNA testing!
Join us at AMP 2026 in Seattle for our talk on NGS RNA Expression as the New Frontier of Diagnostic and Predictive IHC in Oncologic Pathology presented by Dr. Ahmad Charifa.
Learn more: https://t.co/imFuduAead
#AMP26#RNA#Geneexpression
GTC analyzes both DNA and RNA to provide more complete molecular insights, helping clinicians better understand each patient’s cancer and make more informed diagnostic and care decisions.
Learn more: https://t.co/WOmSiNiCT7
#RNA#DNA#CGP#PrecisionMedicine
Join us at AMP 2026 in Seattle for our talk on NGS RNA Expression as the New Frontier of Diagnostic and Predictive IHC in Oncologic Pathology presented by Dr. Ahmad Charifa
Learn more: https://t.co/imFuduAead
#AMP26#RNA#Geneexpression
VAF shows the percentage of DNA carrying a mutation. Tumor load measures mutant molecules per milliliter. Together, they provide complementary insights into molecular changes over time. GTC’s Liquid Trace reports both.
https://t.co/0rwZ8iSxGg
#MRD#LiquidBiopsy#cfDNA#cfRNA
Don't Accept Partial Results
One Bone Marrow Sample. Two Cell Populations. Complete Risk Stratification.
Comprehensive Evaluation for Multiple Myeloma using DNA and RNA Profiling
Learn more: https://t.co/4njGljIwuc
#CD138#Multiplemyeloma#DNA#RNA
Don’t let QNS/TNP fears stop you from ordering comprehensive genomic profiling. Using innovative chemistry helps reduce QNS and TNP rates. GTC's QNS rate is currently less than 1%. Most labs using NGS are greater than >10% QNS/TNP
Read more: https://t.co/T4OlHOTBHp
#QNS
When cancer affects the CNS, look to CSF for the molecular story.
GTC’s Liquid Trace profiles DNA and RNA in CSF to help characterize primary and metastatic CNS disease.
https://t.co/ozqQtyVjcD
#CSF#Liquidbiopsy#CNStumors#glioblastoma
Join us at AMP 2026 in Seattle for our talk on NGS RNA Expression as the New Frontier of Diagnostic and Predictive IHC in Oncologic Pathology presented by Dr. Ahmad Charifa
Learn more: https://t.co/WOmSiNjaIF
#AMP26#RNA#Geneexpression
Check out a case study from our talk at SNO-ASCO and how CSF liquid biopsy helped resolve and aid in the classification of a diagnosis.
https://t.co/Pi8MA3FXbR
Detect CAR-T expression alongside clonality, mutations, fusions, and gene expression through comprehensive DNA and RNA profiling.
Learn more: https://t.co/4njGljIwuc
#CAR_T#Geneexpression#RNA
Check out highlights on Dr. Albitar's talk at the Latin America Cutaneous Lymphoma conference in Bogata Columbia on August 1st.
Link: https://t.co/wE8V2XXnqY
#CTCL#Lymphoma#RNA#Spitzoidtumor
GTC analyzes both DNA and RNA to provide more complete molecular insights, helping clinicians better understand each patient’s cancer and make more informed diagnostic and care decisions.
Learn more: https://t.co/WOmSiNiCT7
#RNA#DNA#CGP#PrecisionMedicine
Join us at AMP 2026 in Seattle for our talk on NGS RNA Expression as the New Frontier of Diagnostic and Predictive IHC in Oncologic Pathology presented by Dr. Ahmad Charifa
Learn more: https://t.co/WOmSiNiCT7
#AMP26#RNA#Geneexpression
Don't Accept Partial Results
One Bone Marrow Sample. Two Cell Populations. Complete Risk Stratification.
Comprehensive Evaluation for Multiple Myeloma using DNA and RNA Profiling
Learn more: https://t.co/4njGljIwuc
#CD138#Multiplemyeloma#DNA#RNA
In recognition of the holiday, our offices will be closed on Monday. We hope everyone enjoys a safe and relaxing holiday weekend! We will be open for business on Tuesday.
#labordayweekend
GTC analyzes both DNA and RNA to provide more complete molecular insights, helping clinicians better understand each patient’s cancer and make more informed diagnostic and care decisions.
Learn more: https://t.co/imFuduAead
#RNA#DNA#CGP#PrecisionMedicine